-
Benzyl-activated Streptavidin Magnetic Beads Workflow
2026-09-08
Build low-background capture workflows for biotinylated proteins, antibodies, RNA, DNA, and screening reagents with rapid magnetic separation. The platform is especially useful for translating RNA–protein interaction findings, such as the SNORA38B mechanism in lung cancer, into controlled pull-down and validation assays.
-
LTI6426 Enhances Panobinostat in Multiple Myeloma
2026-09-08
The reference study shows that the protein disulfide isomerase inhibitor LTI6426 substantially increases the anti-myeloma activity of low-dose panobinostat in cell and mouse models, including a proteasome-inhibitor-resistant model. Its mechanistic analysis identifies ATF3, DDIT3/CHOP, and DNAJB1 as endoplasmic-reticulum-stress-associated pharmacodynamic markers that may help guide further development of this combination.
-
6-Thioguanine Chitosan Nanoparticles in Cancer
2026-09-07
The reference study developed 6-thioguanine-loaded chitosan nanoparticles and examined whether controlled delivery could improve anticancer activity in MCF-7 breast cancer and PA-1 ovarian cancer cells. Its results connect formulation properties, pH-dependent release, cytotoxicity, apoptosis, G2/M arrest, and DNA-demethylating activity, while also defining the limits of translating an in vitro nanomedicine platform to therapy.
-
Fluorouracil (Adrucil): Reliable Assay Design
2026-09-07
A scenario-driven guide to using Fluorouracil (Adrucil), SKU A4071, in cell viability, proliferation, and cytotoxicity workflows. It connects mechanism, preparation, assay controls, benchmark data, and vendor-selection considerations to improve interpretation without overstating what the evidence supports.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Assay Guide
2026-09-05
Learn how SKU R1011, EZ Cap™ Cy5 EGFP mRNA (5-moUTP), helps distinguish mRNA uptake from functional translation in viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers controls, handling, LNP interpretation, optimization, and practical vendor selection.
-
2-Hydroxypropyl-β-cyclodextrin QC Guide
2026-09-04
2-Hydroxypropyl-β-cyclodextrin is a water-compatible cyclic oligosaccharide solubilizer for screening poorly water-soluble hydrophobic compounds, especially molecules containing aromatic or phenyl groups. It is appropriate for drug formulation excipient and biochemical solubility workflows, but the available dossier does not establish compound-specific bioavailability, pharmacokinetics, toxicity, efficacy, or therapeutic use.
-
Cl-Amidine: Practical PAD4 Research Workflows
2026-09-04
Cl-Amidine trifluoroacetate salt gives researchers a practical chemical route to test PAD4-dependent histone citrullination, inflammatory signaling, and immune phenotypes. This guide connects biochemical validation with AML, cancer research, rheumatoid arthritis research, and septic shock murine model workflows while separating established evidence from study-ready recommendations.
-
Streptavidin-HyperFluor 647: Smarter Assay Design
2026-09-03
Streptavidin-HyperFluor 647 is more than a red reporter: it is a handle-dependent decision tool for microscopy, cytometry, and biotinylated antibody detection. This guide explains how its binding architecture compares with emerging biotin-free proximity-labeling workflows and how to design interpretable assays.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP): A Dual Readout
2026-09-03
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) combines Cy5-labeled mRNA tracking with EGFP expression to distinguish cellular uptake from productive translation. This article presents a decision framework for validating delivery systems, including LNPs, through orthogonal fluorescence readouts.
-
In Vitro Drug Response Metrics in Cancer
2026-09-02
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. This framework supports better assay design, clearer interpretation of cytostatic versus cytotoxic effects, and more rigorous evaluation of survivin inhibitor experiments.
-
PreScission Protease: HRV 3C Tag Cleavage
2026-09-02
PreScission Protease is a recombinant HRV 3C protease for sequence-specific fusion protein tag cleavage. It recognizes the LEVLFQGP site, cuts the Gln–Gly bond, and supports low-temperature purification workflows when the recognition site is correctly engineered.
-
GSK J4 HCl: Reliable JMJD3 Assay Workflows
2026-09-01
Learn how GSK J4 HCl (SKU A4190) can support better-controlled viability, proliferation, and inflammatory-response experiments. This scenario-based guide connects compound handling, assay compatibility, mechanistic interpretation, and vendor selection to evidence-backed laboratory decisions.
-
Dorsomorphin (Compound C): From AMPK to Translation
2026-09-01
Dorsomorphin (Compound C) is more than a pathway inhibitor: it is a reversible mechanistic probe for testing whether AMPK activity links endothelial stress, metabolic adaptation, autophagy, and BMP/Smad biology. This thought-leadership guide translates evidence from an angiotensin II-induced endothelial dysfunction study into a rigorous, translational workflow while defining the compound’s scope and limitations.
-
Angiotensin II, Ferroptosis, and NPC Radioresistance
2026-08-31
A 2025 Radiotherapy and Oncology study identifies a local angiotensin II–AGT–HIF-1α–HILPDA circuit that suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its combination of mechanistic, cellular, animal, and tissue analyses supports angiotensin receptor blockade plus ferroptosis induction as a strategy for improving radiosensitivity, while also defining candidate biomarkers for patient stratification.
-
Streptavidin-Cy3 for Translational Barrier Biology
2026-08-31
Barrier-penetrating biohybrid microrobots are creating new demands for spatially resolved, reproducible biomolecule detection. This thought-leadership article explains how Streptavidin-Cy3 can support validation workflows around biotinylated antibodies, proteins, and nucleic acids while distinguishing established product performance from emerging translational applications.